Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login


Degenerative neurological disorders

HRT linked to increased Alzheimer’s disease risk in women

Researchers say users of hormone replacement therapy should be informed of the elevated risk of Alzheimer’s disease associated with its long-term use.

Older woman putting on her HRT patch

Source: Cristina Pedrazzini / Science Photo Library

Overall, the odds of Alzheimer’s disease diagnosis was 9% higher in users of oestradiol-only therapy and 17% higher in users of oestrogen-progestogen therapy

Hormone replacement therapy (HRT) is associated with a small but significantly increased risk of Alzheimer’s disease (AD), research published in The BMJ suggests (6 March 2019)[1].

Study authors looked at data on 84,739 post-menopausal women from Finland diagnosed with AD between 1999 and 2013, matched to an equal number of women without a diagnosis.

Overall, the odds of AD diagnosis was 9% higher in users of oestradiol-only therapy and 17% higher in users of oestrogen-progestogen therapy, but the difference in risk between these two groups was not significant. By contrast, exclusive use of vaginal oestrogen was not associated with increased AD risk.

In absolute terms, the researchers estimated that use of systemic hormone therapy was linked to 9–18 additional AD diagnoses in every 10,000 women aged 70–80 years, especially in those who had taken HRT for at least ten years.

The potential role of HRT in dementia has previously been unclear, with some studies finding it protective and others indicating an increased risk, the researchers explained. 

“Hormone therapy users should be informed of a possible risk of the disease with prolonged use, even though the absolute risk elevations are small,” they said. 


Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206351

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.